Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 26, 2015
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - April 26, 2015

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/26/15 - Court Overseeing Federal Testosterone Treatment Lawsuits Convenes April Case Management Conference
A Case Management Conference was convened on April 21, 2015 in the U.S. District Court, Northern District of Illinois, where hundreds of federally-filed testosterone lawsuits have been consolidated for the purposes of coordinated pretrial proceedings. The Court's discussion pertaining to generic drug cases was especially timely, as the FDA is curre
4/26/15 - United States : Mylan Makes Offer to Acquire Perrigo [TendersInfo (India)]
Davis Polk is advising Goldman Sachs as lender and financial adviser to Mylan N.V. in connection with its proposal to acquire Perrigo Company plc for $60 in cash and 2.2 Mylan shares per Perrigo share. Perrigo is a leading global health care supplier that develops, manufactures and distributes over-the-counter and prescription pharmaceuticals,...
4/25/15 - "Data-Enabled Pharmaceutical Container and Methods for Using Same" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventors Burrows, Mark; Eckhaus, Neal; Grubbe, Donald; Christoffersen, George, filed on October 1, 2013, was made available online on April 9, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This pate
4/25/15 - AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX + EXVIERA in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress? 2015
AbbVie today announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3 b RUBY-I study. "RUBY-I is part of AbbVie's broader Phase 3 b program and demonstrates our continued focus on people living with hepatitis C that have specific needs," said Scott Brun, M.D., vice president, pharmaceutical development, A
4/25/15 - Athersys to Host Shareholder Conference Call [Cihan News Agency (Turkey)]
-Athersys, Inc. announced today that it will be hosting a shareholder conference call on Wednesday, April 29, 2015 to present the recently announced interim results of its exploratory Phase 2 clinical study of the intravenous administration of MultiStem cell therapy to treat patients who have suffered an ischemic stroke. Gil Van Bokkelen, Chairm
4/25/15 - Batavia Biosciences - A new name, in keeping with a recognised market position [Saudi Press Agency (Saudi Arabia)]
"Our new name, Batavia Biosciences, better reflects the added value and scientific support that our company brings to our partners as well as our R&D staff's efforts in developing exciting novel technologies to accelerate biopharmaceutical product development," commented Menzo Havenga, CEO. "Our highly educated and experienced R&D staff is well re
4/25/15 - Competitor Analysis: Therapeutic Antibodies 2015 - Biosimilars & Biosuperiors: Featuring 174 Companies
By a News Reporter-Staff News Editor at Investment Weekly News Research and Markets has announced the addition of the "Competitor Analysis: Therapeutic Antibodies 2015- Biosimilars& Biosuperiors" report to their offering. Total sales of recombinant therapeutic monoclonal antibodies originating from companies located in regulated markets reached U
4/25/15 - Drug cost mystery: older multiple sclerosis medicines skyrocket despite competition [The Oregonian, Portland, Ore.]
Instead of competition driving prices down when superior competing drugs were introduced, costs in the U.S. went up even faster than before, according to the study conducted by researchers at Oregon State University and Oregon Health& Science University. "'Economics 101' would suggest that competition should lower prices," said Daniel Hartung, an
4/25/15 - Enanta Pharmaceuticals Announces Preliminary Data from AbbVie's Phase 3b RUBY-I Study in Chronic Hepatitis C Patients with Renal Impairment Presented at The International Liver Congress? 2015
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced today new preliminary safety and efficacy data from the first cohort of AbbVie s ongoing, Phase 3 b RUBY-I study. The first ten patients, or 100 percent, who have rea
4/25/15 - Germany : Bayer supports cancer biomarker research in Europe [TendersInfo (India)]
Bayer HealthCare and University Medical Center Hamburg-Eppendorf are the main coordinators of the newly founded international consortium CANCER-ID to develop and validate novel blood-based biomarker technologies in cancer. CANCER-ID is a public-private partnership supported by Europe s Innovative Medicines Initiative. The consortium brings...
4/25/15 - INC Research Collaborates With DrugDev to Create Innovative, Cloud-Based Solutions That Drive Increased Efficiencies for Feasibility, Site Selection... [Palestine Chronicle, The]
-INC Research Holdings, Inc., a leading, global Phase I to IV contract research organization, today announced a strategic collaboration with DrugDev to drive increased efficiencies in clinical trials through enhanced access to and management of critical investigator and site data. Under the agreement, INC Research becomes the first CRO to complete.
4/25/15 - Innocoll AG Announces Pricing of Follow-On Offering [Jerusalem Post (Israel)]
-Innocoll AG, a specialty pharmaceutical company, today announced the pricing of its follow-on public offering of 3,321,669 American Depositary Shares at a public offering price of $9.00 per ADS. The offering of these securities is being made only by means of a prospectus, copies of which can be obtained from: Piper Jaffray& Co., Attention: Prospec
4/25/15 - Lipocine Announces Proposed Public Offering of Common Stock [Jerusalem Post (Israel)]
-Lipocine Inc., a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Lipocine expects to grant the underwriters a 30- day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotment
4/25/15 - Lipocine Prices $30.2 Million Public Offering of Common Stock [Jerusalem Post (Israel)]
-Lipocine Inc., a specialty pharmaceutical company, today announced that it has priced an underwritten public offering of 4,650,000 shares of its common stock at $6.50 per share for gross proceeds of $30.2 million. Lipocine has also granted the underwriters a 30- day option to purchase up to an additional 697,500 shares of common stock to cover...
4/25/15 - Mylan raises bid for fellow drugmaker; Perrigo says 'no' [The Pittsburgh Tribune-Review]
April 24 Mylan NV launched a hostile takeover bid for fellow generic drug maker Perrigo Co., telling the company's stockholders Friday it will pay them $31.2 billion if they tender their shares. The board of Ireland- based Perrigo, which makes over-the-counter medicines and nutritional products, urged its shareholders to take no action, arguing t
4/25/15 - The Hartford Courant Jon Lender column [The Hartford Courant]
April 25 Unregulated drugs produced by controversial compounding pharmacies are costing Connecticut taxpayers up to $24 million this year in prescription payments on behalf of state employees and retirees, a stunning 3,000 percent increase from their $800,000 price just three years ago. For example, the compounding pharmacies often use a medicati
4/25/15 - United States : Oral Therapies Are The Next Step for Global Rheumatoid Arthritis Therapeutics [TendersInfo (India)]
The rheumatoid arthritis therapeutics market is dominated by three tumor necrosis factor inhibitors Enbrel, Humira and Remicade. New analysis from Frost& Sullivan, Product and Pipeline Analysis of the Global Rheumatoid Arthritis Therapeutics Market, finds that 40 drugs for the treatment of rheumatoid arthritis are under development.
4/25/15 - United States : Precision Medicine Software Genedata Profiler Launched at Bio-IT World [TendersInfo (India)]
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced at Bio-IT World Conference& Expo 15 the launch of Genedata ProfilerTM, an open, interoperable enterprise software platform designed to facilitate efficient patient and compound profiling processes. The US National Institutes of.
4/25/15 - Zogenix Closes Sale of Zohydro(R) ER Business to Pernix [National News Agency (Lebanon)]
-Zogenix, Inc., a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders, announced today that it has closed the sale of its Zohydro ER business to a wholly-owned subsidiary of Pernix Therapeutics Holdings, Inc. for $80 million in cash, approximately 1.68 million shares of Pernix comm
4/24/15 - "Novel Pharmaceutical Composition of Linezolid" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Panandikar, Aditi; Bambolkar, Sundeep; Inamdar, Kavita; Ramesh, Sapna; Burkul, Amol; Shaikh, Nasir, filed on August 2, 2013, was made available online on April 9, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspondents. Th
4/24/15 - "Smoking Cessation Device" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Health& Medicine Week A patent application by the inventor Park, Andrew Chunkil, filed on October 1, 2014, was made available online on April 9, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspondents. "According to the U.S. Food and Drug Administration, tobacco use is
4/24/15 - ' 350 medicines brought under price control' [Mail Today (India)]
CHEMICAL and fertiliser minister Ananth Kumar told the Lok Sabha on Thursday that 350 drugs had been brought under price control providing additional benefit of more than ` 3,000 crore to customers. The Centre will also come out with incentives to boost bulk drug industry, Kumar said while noting that 60 per cent of drug import costing ` 12,000 cro
4/24/15 - ACCC authorises Medicines Australia code subject to strengthening individual reporting
"The ACCC commends Medicines Australia for introducing transparency to payments provided to individual doctors by drug companies," ACCC Commissioner Dr Jill Walker said. "The ACCC and interested parties have been anticipating this change for a number of years now." The ACCC accepts that this new transparency regime is a significant and important c
4/24/15 - Anavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and to Reveal New Epilepsy Data at Antiepileptic Drug Trials XIII Conference
Release date- 23042015- NEW YORK, NY- Anavex Life Sciences Corp. today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the World Orphan Drug Congress on Thursday, April 23, 2015 at 11:10 a.m. ET at The Washington Hilton in Washington, DC. On Friday, May 15, 2015 at 3:30 p.m. ET, Dr. Missling will
4/24/15 - Anavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and to Reveal New Epilepsy Data at Antiepileptic Drug Trials XIII Conference [Yemen Times]
-Anavex Life Sciences Corp. today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the World Orphan Drug Congress on Thursday, April 23, 2015 at 11:10 a.m. ET at The Washington Hilton in Washington, DC. In a presentation titled "Potential applications of sigma-1 receptors in orphan indications," Dr
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415